Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.

Oral Xa inhibitors prevent recurrent venous thromboembolism in cancer patients

12 Oct 2018

Oral factor Xa inhibitors may be used as potential substitutes for warfarin and low molecular weight heparin for the prevention of recurrent thromboembolism in oncology patients, suggests a recent study. However, randomized controlled trials are warranted to confirm these results.

A total of 127 patients with venous thromboembolism were recruited, of whom 48 received rivaroxaban or apixaban, 23 received enoxaparin, and 56 received warfarin. Lung (21 percent), colorectal (14 percent) and breast (14 percent) were the three most common cancer diagnoses.

At 3 months, no difference was observed between the rivaroxaban/apixaban (0 percent), warfarin (3.6 percent) and the enoxaparin cohorts (4.4 percent; p=0.8319). Only one patient in the enoxaparin arm (4.2 percent) had a major bleeding at 3 months.

Moreover, mortality was 0 percent, 3.6 percent and 17.4 percent in the rivaroxaban/apixaban, warfarin and enoxaparin cohorts, respectively, at 3 months.

In another study, Xing and colleagues found that rivaroxaban was on a par with enoxaparin in terms of safety and efficacy for the prevention of recurrent venous thromboembolism in patients with malignancy, indicating rivaroxaban as a potential option for cancer patients with venous thromboembolism. [Medicine (Baltimore) 2018;97:e11384]

In this study, the authors used retrospectively obtained data to compare the recurrent venous thromboembolism incidence in oncology patients taking rivaroxaban/apixaban, enoxaparin or warfarin with at least 3 months of follow-up. Inclusion criteria for patients were as follows: active cancer, venous thromboembolism, and taking warfarin, enoxaparin or rivaroxaban/apixaban.

The first episode of recurrent venous thromboembolism at 3 months was the primary endpoint, while the secondary endpoints included recurrent venous thromboembolism after 6 months, major bleeding and mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Aug 2018

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

19 Jul 2018
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.